Bounded definition
The cited report describes collection, ex-vivo CRISPR-Cas9 editing, conditioning, transplantation, and early follow-up for two participants. Within this page, that proposition is limited to The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Definition and evidence boundary
A process in which cells are collected, edited and assessed outside the body, then returned under a clinical or experimental protocol. The bounded proposition retained by the canonical record is: The cited report describes collection, ex-vivo CRISPR-Cas9 editing, conditioning, transplantation, and early follow-up for two participants.
The applicable scope is The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. This definition must not be generalized beyond the cited source and exact record boundary.
Claims: urn:maha:claim:ex-vivo-genome-editing-workflow
Mechanism and technical context
The report describes ex-vivo CRISPR-Cas9 editing, conditioning, transplantation, and early clinical outcomes for two participants under a specific investigational protocol. This is the source-bound technical context for the record; no uncited mechanism is added by the compiler.
The workflow’s risks and outcomes are indication-, cell-product-, conditioning-, manufacturing-, participant-, and follow-up-specific. The mechanism or method is therefore presented as one component of a larger system, not as evidence for every downstream outcome.
Claims: urn:maha:claim:ex-vivo-genome-editing-workflow
How to interpret the evidence
There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices. The evidence maturity recorded here is single study, and the claim kind is empirical claim.
This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded. Two early cases do not establish population-level safety, durability, comparative effectiveness, or general readiness of genome editing. These qualifications travel with the claim whenever it is reused.
Claims: urn:maha:claim:ex-vivo-genome-editing-workflow
What the source supports and what remains unknown
The inspected source supports exactly this: The report describes ex-vivo CRISPR-Cas9 editing, conditioning, transplantation, and early clinical outcomes for two participants under a specific investigational protocol. It was read at Abstract; Methods; Results; figures and tables for the two reported participants; supplementary protocol.
What remains unknown is everything outside that locator. The workflow’s risks and outcomes are indication-, cell-product-, conditioning-, manufacturing-, participant-, and follow-up-specific. No quantity, comparison, or downstream outcome is established here unless a separately scoped record measures it.
Claims: urn:maha:claim:ex-vivo-genome-editing-workflow
Source identity, locator, and reuse boundary
The bound source is “CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia” by Haydar Frangoul, David Altshuler, M. Domenica Cappellini, Yi-Shan Chen, et al., published by The New England Journal of Medicine on 2020-12-05; its declared stable identity is doi:10.1056/NEJMoa2031054.
The inspected-content locator is Abstract; Methods; Results; figures and tables for the two reported participants; supplementary protocol. Reuse is limited to citation-with-paraphrase. Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced. This metadata establishes source identity and inspection scope, not the truth of claims outside the cited locator.
Claims: urn:maha:claim:ex-vivo-genome-editing-workflow
Comparison and calculation boundary
Applicability is decided explicitly, not filled with generic material.
This record carries 1 source-bound proposition and therefore has no second supported side. A comparison would have to be manufactured from an adjacent title rather than from a second inspected claim, which the gate forbids.
The canonical claim declares no reproducible numerical inputs, equation, units, or uncertainty propagation; recorded uncertainty kind is qualitative. Supplying sample values would invent an unsupported quantitative result.
Limitations and prohibited inference
The claim stops where its evidence stops.
- record boundary
The workflow’s risks and outcomes are indication-, cell-product-, conditioning-, manufacturing-, participant-, and follow-up-specific.
- record boundary
A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record.
- prohibited inference
Do not treat the ex-vivo genome-editing workflow record as medical advice, a treatment recommendation, or evidence of general clinical readiness.
- prohibited inference
Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract.
- editorial
This compilation reorganizes an existing inspected claim and its declared source; it does not add a new experiment, measurement, or independent replication.
- editorial
Internal editorial inspection is not external peer review, and no result on this page has been independently reproduced.
Related records and mathematical bridges
Typed links expose context without asserting equivalence.
Adenine base editing
Same canonical domain (synthetic-biology). Domain membership only: no shared source or declared edge links these two records.
Selection: domain adjacency
Cell-line versus primary-cell evidence
Declared mechanistic-dependency edge from this record. The edge is navigational and asserts no equivalence or causation beyond the cited source scope.
Selection: bridge edge
Somatic versus germline genome editing
Declared mechanistic-dependency edge from this record. The edge is navigational and asserts no equivalence or causation beyond the cited source scope.
Selection: bridge edge
When no declared bridge edge is present, related records are linked by shared evidence or canonical domain adjacency. Those links are navigational and do not claim mathematical or physical equivalence.
Connected domain graph
Typed dependencies preserve publication state.
Only independently canonical records receive public links and relation statements. Draft graph topology remains private.
Somatic versus germline genome editing
outbound connection · comparison
The reported ex-vivo intervention edits somatic hematopoietic cells rather than reproductive-line cells.
Cell-line versus primary-cell evidence
outbound connection · comparison
The cell product is composed of participant-derived primary cells, not an immortalized line.
Somatic versus germline genome editing
inbound connection · comparison
The cited ex-vivo hematopoietic workflow targets somatic cells and is not a germline intervention.
Claim ledger
Every proposition keeps its own evidence state.
The cited report describes collection, ex-vivo CRISPR-Cas9 editing, conditioning, transplantation, and early follow-up for two participants.
- Scope
- The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
- Boundary
- The workflow’s risks and outcomes are indication-, cell-product-, conditioning-, manufacturing-, participant-, and follow-up-specific.
- Uncertainty
- There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices.
- Replication
- This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.
Primary sources
Citation, locator, rights, and boundary travel together.
Source 1 · The New England Journal of Medicine
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Haydar Frangoul, David Altshuler, M. Domenica Cappellini, Yi-Shan Chen, et al.
- Exact locator
- Abstract; Methods; Results; figures and tables for the two reported participants; supplementary protocol.
- Establishes
- The report describes ex-vivo CRISPR-Cas9 editing, conditioning, transplantation, and early clinical outcomes for two participants under a specific investigational protocol.
- Boundary
- Two early cases do not establish population-level safety, durability, comparative effectiveness, or general readiness of genome editing.
- Rights basis
- citation with paraphrase · Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.
- Declared interests
- The study was sponsored by CRISPR Therapeutics and Vertex Pharmaceuticals; author relationships are disclosed in the article.